RESEARCH USE ONLY. Reference data for laboratory research. Not medical advice; not for human consumption.
Peptijournal
Calc

Compare compounds

Pick up to 3 compounds to see protocols, mechanisms, study endpoints and safety findings side by side.

PopularRetatrutide vs TirzepatideSemaglutide vs TirzepatideSemaglutide vs RetatrutideBPC-157 vs TB-500BPC-157 vs GHK-CuSermorelin vs Tesamorelin
AOD-9604
Same goal
Include when printing

Only affects the printed page / PDF. The research-use-only notice always prints.

Protocol01
AOD-9604

Metabolic / Weight

Vials · 2 / 5 mg

01Protocol

Vials
2 / 5 mg
Dosing data
Lab reference — not listed

02Quick calculator

Draw (100u)

—

Concentration

—

mg/mL

03Mechanism of action

AOD-9604 is a modified fragment of the C-terminal region of human growth hormone, developed to study fat metabolism without growth hormone's growth-promoting effects.

04Study endpoints

  • It was developed by Metabolic Pharmaceuticals as a potential obesity treatment and had reached phase IIa trials by February 2002.
  • A 2026 sports-medicine review groups it with unapproved peptides that look favourable in animal models but have scarce rigorous human safety data.

05Safety & regulatory findings

  • Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
  • Listed as prohibited in sport by the World Anti-Doping Agency.
  • Reviewers warn of potential for serious harm when unapproved peptides are used outside regulatory oversight.

06Citations

2 references · view